Serino Ma Dana, Peterson Md Bradley S, Rosen Md Tove S
a School of Psychology , Fairleigh Dickinson University , Teaneck , New Jersey , USA.
b Children's Hospital of Los Angeles, Institute for the Developing Mind, Keck School of Medicine , University of Southern California , Los Angeles , California , USA.
J Dual Diagn. 2018 Jul-Sep;14(3):158-170. doi: 10.1080/15504263.2018.1468946. Epub 2018 Sep 5.
The aim of this research was to assess psychosocial history and psychological functioning in women who use drugs during pregnancy and determine how drug exposure affects child development.
Pregnant women using marijuana (n = 38) and cocaine (n = 35) and receiving methadone maintenance (n = 24), along with a control (n = 49) group of pregnant women, were enrolled and followed every six months through 18-24 months postnatally.
There was a significantly higher incidence of mental illness among mothers in the drug-using groups. Prenatal stress and late-term drug severity scores were significantly higher in the mothers who used cocaine and methadone, who were also more likely to have abuse and incarceration histories. At 12 months, there were significantly higher rates of drug use in the marijuana group. Anxiety scores were highest in the methadone group. At 18 to 24 months, the methadone group reported significantly more stress, and methadone and marijuana groups had significantly higher anxiety and depression scores. At birth, neonates from the methadone and marijuana groups had significantly smaller head circumferences, with the smallest values in the methadone group. At one year, children in the cocaine group had significantly lower Bayley Scales of Infant Development-Third Edition (Bayley-III) cognitive and motor scores. At 18 to 24 months, children in the methadone group had significantly smaller head circumferences and Bayley-III cognitive scores. Children in the methadone and cocaine groups had a significantly higher incidence of atypical neurological examinations at 6 to 9 and 18 to 24 months.
Mothers in the methadone and cocaine groups presented with more severe prenatal drug use and psychosocial risk factors relative to women who used primarily marijuana. Children in the cocaine and methadone groups were neurologically atypical relative to others at study end. Mothers in the marijuana group reported chronic drug use as well as anxiety and depression at follow-up. At birth, children in the marijuana group were smaller, but this resolved with time. Similarly, children in the cocaine group had motor and cognitive delays that resolved by age two. Children in the methadone group had persistent growth and cognitive deficits. Their mothers demonstrated more anxiety, depression, and stress, the combination of which left these women and children liable to face ongoing psychosocial struggle and psychological distress. Dual interventions for mother and child should be considered in attempting to optimize outcome.
本研究旨在评估孕期吸毒女性的心理社会史和心理功能,并确定药物暴露如何影响儿童发育。
招募了使用大麻的孕妇(n = 38)、使用可卡因的孕妇(n = 35)以及接受美沙酮维持治疗的孕妇(n = 24),并与一组对照孕妇(n = 49)进行对比,在产后18 - 24个月期间每六个月进行一次随访。
吸毒组母亲的精神疾病发病率显著更高。使用可卡因和美沙酮的母亲产前压力和晚期药物严重程度评分显著更高,她们也更有可能有滥用药物和入狱史。在12个月时,大麻组的吸毒率显著更高。美沙酮组的焦虑评分最高。在18至24个月时,美沙酮组报告的压力显著更多,美沙酮组和大麻组的焦虑和抑郁评分显著更高。出生时,美沙酮组和大麻组的新生儿头围显著更小,美沙酮组的值最小。在1岁时,可卡因组儿童的贝利婴儿发展量表第三版(Bayley - III)认知和运动评分显著更低。在18至24个月时,美沙酮组儿童的头围和Bayley - III认知评分显著更小。美沙酮组和可卡因组的儿童在6至9个月以及18至24个月时非典型神经学检查的发生率显著更高。
与主要使用大麻的女性相比,美沙酮组和可卡因组的母亲产前药物使用和心理社会风险因素更为严重。在研究结束时,可卡因组和美沙酮组的儿童在神经学方面表现异常。大麻组的母亲在随访中报告有长期吸毒以及焦虑和抑郁情况。出生时,大麻组的儿童体型较小,但随着时间推移这种情况得到缓解。同样,可卡因组的儿童有运动和认知延迟,到两岁时得到缓解。美沙酮组的儿童有持续的生长和认知缺陷。他们的母亲表现出更多的焦虑、抑郁和压力,这些因素综合起来使这些女性和儿童容易面临持续的心理社会挣扎和心理困扰。在试图优化结果时,应考虑对母婴进行双重干预。